PharmaLectures.com

Courses › Regulatory affairs by region › United States: ANDA from A to Z, filing a generic without the refuse-to-receive letter

United States: ANDA from A to Z, filing a generic without the refuse-to-receive letter

Your team files generics that clear the agency's filing review the first time.

  • 15 audio modulesthree lengths each
  • 2 h 30 min to 12 h 30 minbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • RA, QA, BDwho it is written for

Why this training matters

The Abbreviated New Drug Application reaches the agency on a Friday. Weeks later a refuse-to-receive letter arrives because a section is missing. Your regulatory team rebuilds the electronic submission, and a competitor's complete filing takes the first-to-file place you planned for.

What changes after this course

Your team checks each section against the filing review before it ships and answers reviewer questions early. You hold a certificate for every learner and a training record for each person, ready for your files. Regulatory, quality and business development work from one plan.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your business development analyst reads the Orange Book entry and tells you on the spot whether the target needs a Paragraph III or Paragraph IV certification, a section viii carve-out, or a pass. The call is made under section 505(j) of the Federal Food, Drug, and Cosmetic Act and the Hatch-Waxman Act before a single formulation batch is made.

Formulation scientists write the pharmaceutical development report with the quality target product profile and critical quality attributes already in it, so the chemistry, manufacturing, and controls sections hold up under Part 314.94. Study leads pick the product-specific guidance first and size the bioequivalence study to it, which ends the repeat study.

Before anything ships, the electronic Common Technical Document gets checked for the gaps that bring a refuse-to-receive letter under Part 314.101: missing impurity specifications, a supplier Drug Master File that does not cover the substance, a label with no side-by-side comparison, and for broken links that fail gateway validation. Regulatory affairs finds them in the draft, not in the agency's letter.

When a Complete Response Letter or an inspection notice lands, nobody waits for a meeting to decide who does what. The reply goes point by point, the batch records and validation reports are indexed, and a site or process change is sorted under Part 314.70 before it reaches the agency.

Who needs this training

  • Regulatory Affairs Specialist

    Two days before the filing date, a hyperlink breaks in Module 3 and the cross-references no longer match. The specialist works from a layout and a check that catch it before the gateway does.

  • Quality Assurance Manager

    The inspector asks for the validation report and the batch record for the exhibit batch, and the room goes quiet. The manager has both indexed, with a plain answer ready for each question.

  • Business Development Analyst

    A promising target turns out to carry a listed patent and a competitor already planning a first-day filing. The analyst spots the Paragraph IV risk before development money is committed.

  • R&D Project Lead

    The bioequivalence results come back and the confidence interval misses because the study was undersized. The lead sizes against the product-specific guidance first, so the clinical work is done once.

Roles: Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: every kind of pharma company

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: United States

Courses are in English. Other languages on request.

After this course your people can

  1. Choose between a Paragraph III certification, a Paragraph IV certification and a section viii statement for a named drug, using its Orange Book listing.
  2. Draft controlled correspondence that asks one clear question and gets a clear answer from the agency.
  3. Size a bioequivalence study against the product-specific guidance before the first subject is dosed.
  4. Assemble an electronic Common Technical Document whose modules and hyperlinks pass gateway validation.
  5. Write a point-by-point reply to a Complete Response Letter that the reviewer can check against each deficiency.
  6. Audit a manufacturing site for pre-approval inspection readiness, starting with the batch records and validation reports inspectors request first.
  7. Sort a post-approval change into prior approval supplement, changes being effected, or annual report under Part 314.70.

What the company gets

  • Your filing reaches the agency complete, so the filing review ends in acceptance and not in a refuse-to-receive letter.
  • Regulatory affairs answers information requests promptly, which keeps the application on its review clock.
  • Quality hands the inspector the validation reports and batch records on request, with no search through shared drives.
  • Business development drops targets that a listed patent blocks and files first on the ones that are open.
  • Each learner has a certificate and a training record in your files, so a client or inspector sees who was trained.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 15 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h 30 min10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard6 h 15 min25 min a module, for regulatory, quality and business-development staff
Expanded12 h 30 min50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Business development and export salesBriefing2 h 30 min
Regulatory affairsStandard6 h 15 min
Quality assurance and Qualified PersonStandard6 h 15 min

Course outline: 15 modules

15 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Build your generic strategy on the Hatch-Waxman Act

    • How section 505(j) lets you rely on the reference drug's findings instead of repeating its trials.
    • The sameness points the agency checks against the Reference Listed Drug, so a mismatch shows up early.
    • Why the Orange Book entry for your target decides what you can file, and when.
  2. 2Choose the right Abbreviated New Drug Application pathway

    • When a Paragraph IV certification fits your target and when Paragraph III is the safer route.
    • What to do when a suitability petition is the only way to a different strength or dosage form.
    • What to do when the Orange Book still lists patents on your target drug, before you commit.
  3. 3Get agency answers in writing before you file

    • How to word controlled correspondence so the agency answers instead of pointing you to a guidance.
    • The data to bring to a pre-submission product development meeting so it ends with a decision.
    • Why a written agency answer on your test plan is worth keeping on file when the review team changes.
  4. 4Build Quality by Design into your generic formulation

    • How a quality target product profile written in month one fixes your formulation choices later.
    • The critical quality attributes reviewers look for in your pharmaceutical development report.
    • What to show in the development report so a reviewer sees a process under control, not a lucky batch.
  5. 5Design bioequivalence studies that pass agency review

    • How to find your drug's product-specific guidance and match your study design to it line by line.
    • The ninety percent confidence interval test reviewers apply to your test and reference products.
    • Why an underpowered study can send you back to the clinic, and how to size yours first.
  6. 6Draft the drug substance section under Part 314.94

    • How to check that your supplier's Drug Master File covers what your application needs.
    • The impurity specification gaps that draw an early information request, and how to close them.
    • What reviewers want in drug substance stability data before they accept your retest period.
  7. 7Document drug product manufacturing and controls that reviewers accept

    • How to describe the manufacturing process so a reviewer sees a batch you can repeat, not a one-off.
    • The master batch record details that the agency compares with your filed process.
    • What to do when you must change a manufacturing site while your application is still under review.
  8. 8Draft labeling that matches the Reference Listed Drug

    • How to build a side-by-side comparison that shows every label difference from the Reference Listed Drug.
    • The label differences the agency allows, and the formatting slips that still get a label sent back.
    • When a carve-out under section viii is worth the label change and when it is not.
  9. 9Structure your electronic Common Technical Document for the gateway

    • How to lay out modules one through five so the electronic gateway takes your file the first time.
    • The broken hyperlinks and bookmark errors that make a reviewer stop reading, and how to catch them.
    • What belongs in Module 1, the regional section, for a United States generic filing.
  10. 10Track your application through each agency review stage

    • How goal dates under the Generic Drug User Fee Amendments tell you when to expect each agency action.
    • The filing review that decides whether you get a refuse-to-receive letter, and what it checks.
    • Why an information request is your last cheap chance to fix a gap before a Complete Response Letter.
  11. 11Answer Complete Response Letters quickly and completely

    • How to answer a chemistry, manufacturing, and controls deficiency without rebuilding the application.
    • The right way to supply missing bioequivalence data when the agency asks for more.
    • Why a point-by-point reply keyed to each deficiency makes the reviewer's work easy.
  12. 12Pass your pre-approval inspection without observations

    • How to run a mock audit against current Good Manufacturing Practice before the inspector arrives.
    • The batch records an inspector pulls first, and how to have them indexed and ready.
    • Why a missing validation report can hold your approval, and where to find the gap first.
  13. 13Handle post-approval changes under Part 314.70

    • How to sort a change into prior approval supplement, changes being effected, or annual report.
    • The three-working-day clock for a field alert report, and who in your company must start it.
    • What your annual report must contain to keep your approved status clean.
  14. 14Assess patent litigation risk under the Hatch-Waxman Act

    • How a patent suit filed within forty-five days of your notice letter triggers a thirty-month stay.
    • The notice letter contents your team must prepare when you certify under Paragraph IV.
    • Why bringing legal in before you choose the target protects your launch date.
  15. 15Secure the first-to-file advantage for your generic

    • How to check the competitive field before you commit development money to a target.
    • The rules for keeping the 180-day head start, and the forfeiture events that take it away.
    • Why business development and technical teams need one timeline to file on the first day.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

15 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h 30 min in the briefing length and 12 h 30 min in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for RA, QA, BD. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 135 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team